ALEEM A SYED
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism ANAHEIM, CA NPI 1003828641
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism CA Amgen Inc. All categories
General Payments — all program years on this page
$13,341.23
- Category: General Payments
- Program years: PY2018–2024
- Record count: 691
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $2,276.91 across 104 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,276.91 | 104 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $381.76 | 23 |
| Lilly USA, LLC | $325.75 | 15 |
| Abbott Laboratories | $177.29 | 7 |
| Insulet Corporation | $176.95 | 7 |
| Kyowa Kirin, Inc. | $176.59 | 3 |
| RECORDATI_RARE_DISEASES_INC. | $138.11 | 5 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $132.59 | 6 |
| Antares Pharma, Inc. | $91.60 | 4 |
| Medtronic, Inc. | $83.99 | 4 |
| Xeris Pharmaceuticals, Inc. | $72.48 | 3 |
| Ascendis Pharma Inc | $62.77 | 3 |
| DEXCOM, INC. | $60.15 | 3 |
| ABBVIE INC. | $42.64 | 2 |
| BOSTON SCIENTIFIC CORPORATION | $37.82 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $33.40 | 2 |
| Novo Nordisk AS | $31.65 | 2 |
| MannKind Corporation | $31.16 | 2 |
| CeQur Corporation | $28.77 | 1 |
| Rhythm Pharmaceuticals, Inc. | $27.32 | 1 |
| Neurocrine BioSciences, Inc. | $22.40 | 1 |
| SANOFI-AVENTIS U.S. LLC | $21.61 | 1 |
| IBSA Pharma Inc. | $20.24 | 1 |
| BETA BIONICS, INC. | $19.02 | 2 |
| Alexion Pharmaceuticals, Inc. | $18.41 | 1 |
| Amphastar Pharmaceuticals, Inc. | $18.11 | 1 |
| TheracosBio, LLC | $16.37 | 1 |
| Astellas Pharma US Inc | $14.21 | 1 |
| TOLMAR, INC. | $13.75 | 1 |
By program year
Records — PY2024 (104)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.